Other Potential Indications
BeyondSpring plans to initiate a broad program with triple combinations in immuno-oncology. Two types of triple combinations will be initiated: first, PD1-inibitor/CTLA4-inhibitor/Plinabulin and second, PD1-inhibitor/chemotherapy/Plinabulin.
In Phase 1 safety studies of Plinabulin in combination with Nivolumab for the treatment of non-small cell lung cancer (NSCLC), which were conducted by collaborators at the Fred Hutchinson Cancer Research Center (Study 202), and University of California, San Diego (Study 201), no grade 3/4 immune-related adverse events were observed in the first 10 patients.
Plinabulin also appears to be a PDE4-inhibitor at clinically relevant doses. PDE4-inhibitors are potent anti-inflammatory agents that are approved to-date to treat inflammatory disorders like eczema, psoriasis and chronic obstructive pulmonary disease (COPD), with resemblance to immune-related adverse events (IR-AEs) as observed with checkpoint inhibitors.